Protocol Number: 99-H-0048

Title:

Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy

Number:

99-H-0048

Summary:

Magnetic resonance imaging (MRI) and spectroscopy are diagnostic tools that create high quality images of the human body without the use of X-ray (radiation). MRI uses different levels of magnetic fields to create images of the body and organs. Occasionally, researchers will give patients undergoing a MRI an injection of a contrast substance. The contrast substance works by brightening areas of the magnetic resonance image.

In this study researchers plan to use magnetic resonance imaging with contrast substances and exercise on normal volunteers in order to evaluate different aspects of its performance. Information gathered from this study may be used to develop more specific research studies involving MRI.

Sponsoring Institute:

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): Children

Eligibility Criteria:

INCLUSION CRITERIA:

Any normal volunteer above the age 18 who is capable of giving informed consent will be included.

EXCLUSION CRITERIA:

A subject will be excluded if he/she has a contradiction to MR scanning.

1) Brain aneurysm clip

2) Implanted neural stimulator

3) Implanted cardiac pacemaker implanted defibrillator

4) Cochlear implant

5) Ocular foreign body (e.g. metal shavings)

6) Insulin pump

7) Pregnant women (when uncertain, subjects will undergo urine or blood testing).

8) Kidney

9) Paralyzed hemidiaphragm

10) Morbid obesity

11) Claustrophobia

12) Any condition in the PI's judgement which present unncessary risk

EXCLUSION CRITERIA FOR GADOLINIUM ENHANCED STUDIES:

1) Lactating women

2) Subjects with hemoglobinopathies

3) Asthma

4) Renal or hepatic disease

Subjects will be excluded if it is deemed that they have a condition that would preclude their use for technical development (e.g. paralyzed hemidiaphragm, morbid obesity, claustrophobia etc.) or present unnecessary risk (e.g. pregnancy, surgery of uncertain type, etc.).

Lactating women and subjects with hemoglobinopathies, asthma, or renal or hepatic disease will be excluded from studies involving the adminstration of contrast agents.

Special Instructions:

Currently Not Provided

Keywords:

Imaging

Spectroscopy

MRI

Cardiovascular

Technical Development

Safety

Gadolinium

Heart

Toxicity

Adverse Events

Recruitment Keyword(s):

Normal Volunteer

Condition(s):

Cardiovascular Disease

Healthy

Investigational Drug(s):

None

Investigational Device(s):

None

Intervention(s):

None

Supporting Site:

National Heart, Lung and Blood Institute

Contact(s):

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):

Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentate-dimeglumine-enhanced dynamic magnetic resonance imaging

Brain mapping with functional MR imaging: comparison of gradient-echo-based exogenous and endogenous contrast techniques

Tolerance data of Gd-DTPA: a review

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Clinical Research Informatics, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 01/13/2009